Table 2 Baseline characteristics before and after propensity score matching
Characteristic | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
Biopsy (n = 401) | No-biopsy (n = 609) | Standardized difference | Biopsy (n = 308) | No-biopsy (n = 308) | Standardized difference | |
Sex (%) | 0.0803 | 0.0032 | ||||
Male | 67.8% | 75.9% | 73.7% | 74.0% | ||
Female | 32.2% | 24.1% | 26.3% | 26.0% | ||
Age | 0.3042 | 0.0455 | ||||
Distribution (%) | ||||||
≤ 59 years | 44.1% | 44.2% | 50.3% | 42.5% | ||
60–69 years | 18.2% | 35.0% | 17.2% | 30.5% | ||
70–79 years | 14.7% | 11.5% | 14.9% | 16.2% | ||
≥ 80 years | 22.9% | 9.4% | 17.5% | 10.7% | ||
Emergency symptoms (%) | 0.1469 | 0.0617 | ||||
Melena | 27.2% | 41.9% | 35.1% | 41.2% | ||
hematemesis | 72.8% | 58.1% | 64.9% | 58.8% | ||
Forrest classification (%) | 0.2534 | 0.0552 | ||||
Ib | 28.7% | 54.0% | 37.0% | 42.5% | ||
Ia | 71.3% | 46.0% | 63.0% | 57.5% | ||
Blatchford score | 14.44 ± 2.80 | 13.50 ± 2.37 | 0.9414 | 13.92 ± 2.72 | 13.63 ± 2.27 | 0.0990 |
Antithrombotics (%) | 0.1358 | 0.0899 | ||||
Non-use | 41.1% | 44.3% | 44.2% | 43.5% | ||
Aspirin | 41.9% | 49.1% | 37.3% | 42.6% | ||
Clopidogrel | 17.0% | 6.6% | 18.5% | 13.9% | ||
HP (%) | − 0.0425 | − 0.0422 | ||||
Yes | 61.6% | 65.8% | 63.3% | 67.5% | ||
No | 38.4% | 34.2% | 36.7% | 32.5% | ||
Pathology results | 0.1643 | 0.0584 | ||||
Malignancy | 40.4% | 24.0% | 36.0% | 30.2% | ||
Benign | 59.6% | 76.0% | 64.0% | 69.8% | ||
Ulcer diameter (%) | 0.3713 | 0.0422 | ||||
< 1 cm | 21.4% | 44.0% | 26.9% | 38.3% | ||
1–1.9 cm | 52.1% | 43.2% | 56.2% | 42.2% | ||
2–2.9 cm | 23.2% | 10.5% | 16.9% | 14.9% | ||
≥ 3 cm | 3.2% | 2.3% | 0.0% | 4.5% | ||
Transfusion (%) | 0.2341 | 0.0812 | ||||
Yes | 74.3% | 50.9% | 66.6% | 58.4% | ||
No | 25.7% | 49.1% | 33.4% | 41.6% | ||
Diabetes (%) | − 0.0138 | 0.0357 | ||||
Yes | 28.2% | 29.6% | 30.5% | 26.9% | ||
No | 71.8% | 70.4% | 69.5% | 73.1% | ||